LONDON: Prime Minister Keir Starmer is treading a fine line on UK-EU relations as hard-right populists make gains at a time when Brexit and immigration remain toxic issues in Britain.
The Labour leader will host European Union chiefs in London on Monday for a major summit designed to progress a deeper relationship between the UK and the bloc than the one negotiated by the previous Conservative government.
But Starmer will be wary of giving ammunition to arch-Euroskeptic Nigel Farage’s Reform UK party, while also conscious that US President Donald Trump views the EU negatively.
“He’s walking two tightropes at the same time,” said British foreign policy expert Richard Whitman, describing immigration as a “salient” issue in the UK and Trump’s attitude to the EU as “hostile.”
“Starmer is balancing this big international issue and also the domestic politics one, and that’s what makes it so tricky for the prime minister,” the politics professor told AFP.
The anti-immigration Reform was founded in 2018 — two years after Britons voted to leave the EU — as the Brexit Party, with the aim of advocating for Britain to depart the bloc without a withdrawal agreement.
Renamed the Reform UK Party in 2021, it has gained significant ground.
Last month, it won more than 670 local council seats, its first two mayoral posts, and gained an additional parliamentary MP in local English elections.
Farage’s upstarts are also leading national opinion polls as they tap into concerns about net migration, which stood at 728,000 in the 12 months to last June, and the struggling economy.
Starmer hopes closer relations with the bloc can spur his main ambition of economic growth but he has vowed to honor the Brexit result, not rejoin the single market, customs union or return to free movement of people.
He has been publicly reticent about an EU-proposed youth mobility scheme that would allow British and European 18- to 30-year-olds to study and work in the UK and vice versa, although the UK government has made warmer noises in recent weeks about a possible controlled program.
An announcement seems unlikely on Monday given that it comes just a week after Starmer said he wanted to “significantly” reduce immigration in a speech intended to appeal to potential Reform voters.
“To announce something like that would be a bit perilous politically,” said Whitman, deputy director of the Global Europe Center at the University of Kent.
Starmer and EU bosses Ursula von der Leyen and Antonio Costa are instead expected to seal a defense pact at the summit — a deal seen as the lowest hanging fruit for negotiators.
“There’s nothing in his proposals that is a dial-shifter in terms of economic growth,” said Anand Menon, director of the UK in a Changing Europe think-tank.
While Starmer is squeezed on the right, he is also under pressure from pro-European lawmakers within Labour who want him to get closer to the EU.
“We must not let Brexit hold us back from our national interest,” Stella Creasy, chair of the Labour Movement for Europe group, told AFP.
“Both sides must move on from the disagreements and red lines to seeking to reduce the paperwork and red tape we face as a result.”
A poll for the internationalist think-tank Best for Britain last month found that 53 percent of voters believe a closer relationship with the EU would be positive for the UK economy.
Britain’s traditional third party, the Liberal Democrats, wants to rejoin the single market and is also surging in popularity, as are the left-wing Greens as UK politics fractures.
“I think Labour are underplaying the danger of losing votes to their left,” said Menon.
He thinks Starmer — who voted to remain at the 2016 referendum — can afford to be bolder considering his 156-majority in parliament and the fact that Reform only has five out of 650 MPs.
“Everything is done in a sort of defensive crouch,” Menon said of the prime minister’s approach.
“It’s kind of apologetic, rather than, ‘This is what I think is good for the country, this is why I’m doing it’.
“I would advise him to start winning the argument.”

PROVIDENCE, Rhode Island: President Donald Trump’s new pick for surgeon general wrote in a recent book that people should consider using unproven psychedelic drugs as therapy and in a newsletter suggested her use of mushrooms helped her find a romantic partner.
Dr. Casey Means’ recommendation to consider guided psilocybin-assisted therapy is notable because psilocybin is illegal under federal law. It’s listed as a Schedule 1 drug, defined as a substance “with no currently accepted medical use and a high potential for abuse.” Oregon and Colorado have legalized psychedelic therapy, though several cities in Oregon have since banned it.
The surgeon general’s job is to provide Americans with the best scientific information available on how to improve their health and reduce their risk of illness and injury. Past surgeons general have used their position to educate Americans about health problems like AIDS and suicide prevention. The surgeon general’s warning in 1964 about the dangers of smoking helped change the course of America’s health.
Some, like Dr. C. Everett Koop, surgeon general under President Ronald Reagan, became widely known with substantial impact on policy, and others slipped easily from memory.
Means’ nomination follows a pattern from Trump to select people known for their public personas more than their policy positions. In the case of Means, the Republican president said he chose her solely on the recommendation of Health Secretary Robert F. Kennedy Jr. “Bobby thought she was fantastic,” Trump said, adding that he did not know her.
Means, who received her undergraduate and medical degrees from Stanford University, began a medical residency in Oregon but did not complete it. Her medical license is listed as inactive. Contacted by phone, Means declined to comment on the record.
She made the recommendation about psychedelics in her 2024 book, “Good Energy,” which she wrote with her brother, Calley Means, an entrepreneur who now works in the Trump administration as a health adviser and who has said he invested in biopharmaceutical companies that specialize in psychedelics.
Much of the book focuses on metabolic health, what Casey Means calls “good energy.” She suggests a number of strategies to help people “manage and heal the stressors, traumas, and thought patterns that limit us and contribute to our poor metabolic health and thriving.”
One such strategy is to “consider psilocybin-assisted therapy,” referring to the compound found in psychedelic mushrooms. She details her thinking on the subject in a 750-word passage.
“If you feel called, I also encourage you to explore intentional, guided psilocybin therapy,” she wrote. “Strong scientific evidence suggests that this psychedelic therapy can be one of the most meaningful experiences of life for some people, as they have been for me.”
Though there have been some studies suggesting benefits from psychedelics, it has not been shown that benefits outweigh the risks. Psilocybin can cause hours of hallucinations that can be pleasant or terrifying. When paired with talk therapy, it has been studied as a treatment for psychiatric conditions and alcoholism, but very little research has been done in healthy people. Side effects can include increased heart rate, nausea and headaches. Taking it unsupervised can be dangerous. Hallucinations could cause a user to walk into traffic or take other risks.
Means wrote that psilocybin and other psychedelics have been stigmatized. She touted the benefits of MDMA, also known as ecstasy or molly, for helping people with post-traumatic stress disorder, or PTSD. The Food and Drug Administration last year declined to approve the use of MDMA as a therapy for PTSD after a panel of advisers found the research was flawed and there were significant risks in using it.
Means refers to psychedelics in her book as “plant medicine.” She describes how she took mushrooms for the first time around Jan. 1, 2021, after she was inspired by “an internal voice that whispered: it’s time to prepare.”
“I felt myself as part of an infinite and unbroken series of cosmic nesting dolls of millions of mothers and babies before me from the beginning of life,” she wrote, adding that in her experience “psilocybin can be a doorway to a different reality that is free from the limiting beliefs of my ego, feelings, and personal history.”
In a newsletter she published in October, Means said she had also used psychedelics to help her make “space to find love at 35.” She wrote that she “did plant medicine experiences with trusted guides” to become ready for partnership, punctuating the line with a mushroom emoji. She noted she was not necessarily making recommendations that others do the same.
In a post this month about her White House health policy wish list, Means said she wanted more nutritious food served in schools, suggested putting warning labels on ultra-processed foods, called for investigations into vaccine safety and said she wanted to remove conflicts of interest. She did not specifically mention psychedelics but said that researchers have little incentive to study “generic, natural, and non-patentable drugs and therapies” and that a portion of research budgets should be devoted to alternative approaches to health.
Calley Means has also advocated for the use of psychedelic drugs, writing in a 2021 blog post that he first tried psilocybin during a challenging time in his life and “it was the single most meaningful experience of my life — personally, professionally, and spiritually.” He said in 2022 that he had “sold all of my 401k” and bought stocks in two companies that are developing and researching psychedelics. He did not respond to messages seeking comment.
Casey Means’ confirmation hearing has not been scheduled. Trump chose Means after questions were raised about the resume of his first pick for surgeon general, former Fox News medical contributor Janette Nesheiwat, and he withdrew her nomination.